CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.

Microplastics: Invisible to the eye but severely harmful to pregnancy and metabolic outcomes

The effects of polystyrene microplastics on pregnancy outcomes and glucose metabolism.

May 29, 2024

EMA validates BMS’ Opdivo application for bladder cancer – Pharmaceutical Technology

The Phase III data was presented at the European Society for Medical Oncology (ESMO) Congress 2023. Credit: OGphoto via Getty Images. Bristol Myers Squibb’s (BMS)

October 30, 2023

Running helps to prevent weight or fat gain in the long-term, study shows

Recently, some media outlets have highlighted that it is a myth that running will help you lose weight/fat.

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.